Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Neumora Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Neumora Therapeutics, Inc. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Neumora Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Neumora Therapeutics, Inc.. Customers appear here when Neumora Therapeutics, Inc. names them, or when a company names Neumora Therapeutics, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pursuant to the 2015 TSRI License Agreement, TSRI granted us a worldwide, exclusive license under certain patent rights and a worldwide, non-exclusive license under certain know-how relating to TSRI's Kappa Opioid Receptor ("KOR" or "navacaprant"), V1aR Receptor ("V1aR" or "NMRA-511") Antagonist and oxytocin receptors ("OTR") positive allosteric modulator programs (collectively, the "TSRI Programs"), in each case that is sublicensable under certain conditions, to use, manufacture and commercialize products (i) that are covered by the relevant licensed patents, (ii) that involve the use or incorporation of the licensed know-how or (iii) that are KOR, V1aR or OTR modulators discovered by BlackThorn within two years of the effective date of the 2015 TSRI License Agreement for the diagnostic, prophylactic and/or therapeutic treatment of humans and animals.”
FILING10-K0001193125-26-130388cik 0001885522
“Neumora exclusively licensed certain intellectual property rights related to NMRA-861 and NMRA-898 from the Warren Center for Neuroscience Drug Discovery at Vanderbilt University.”
FILING10-K0001193125-26-130388cik 0001885522
“The Amgen Collaboration Agreement automatically terminated upon its third anniversary in September 2024 and a final payment was made to Amgen in May 2025.”
FILING10-K0001193125-26-130388cik 0001885522
“In May 2025, we entered into a loan and security agreement, (as amended, the "Loan Agreement") with K2 HealthVentures LLC ("K2HV").”
FILING10-K0001193125-26-130388cik 0001885522
“In October 2024 we entered into a sales agreement with Leerink to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $300.0 million, through an at-the-market equity offering program ("ATM") with Leerink as the sales agent.”
FILING10-K0001193125-26-130388cik 0001885522
“Pursuant to the terms of the Vanderbilt License Agreement, we are required to pay Vanderbilt contingent consideration payable in cash up to an aggregate of $42.0 million upon the achievement of specified development milestones and up to an aggregate of $380.0 million upon the achievement of commercial milestone events as well as tiered royalties at mid-single digit percentages on potential future net sales.”
FILING10-K0001193125-26-130388cik 0001885522
Watchlist prices, news filtered to it, and its next report on your desk.
NMRA (Neumora Therapeutics, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
No intraday reading yet this session.